Compare

Opko Health, Inc. vs Organogenesis Holdings Inc. vs HUTCHMED (China) Ltd vs Amphastar Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearOpko Health, Inc.
OPK
Organogenesis Holdings Inc.
ORGO
HUTCHMED (China) Ltd
HCM
Amphastar Pharmaceuticals, Inc.
AMPH
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$606.88M$564.17M$548.51M$719.89M
Revenue growth (YoY)-14.9%+17.0%-13.0%-1.7%
Gross margin33.9%n/a38.7% (computed)49.5%
Operating margin-19.3%7.9%-7.1%19.5%
Net margin-37.2%6.6%83.3%13.6%
Net income-$225.68M$37.03M$456.91M$98.09M
EPS (Diluted)-$0.30$0.15$0.52$2.03
Operating cash flow-$178.54M-$10.31M-$64.66M$156.12M
Free cash flow-$190.82M-$24.46M-$78.81M$121.23M
Cash & equivalents$364.41M$93.68M$71.33M$170.18M
Total assets$1.93B$598.73M$1.75B$1.63B
Total liabilities$663.99M$164.81M$501.83M$840.49M
Shareholders' equity$1.27B$300.13M$1.25B$788.80M
Return on year-end equity-17.8%12.3%36.5%12.4%
Shares outstandingn/a126.95Mn/a45.65M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearOpko Health, Inc.Organogenesis Holdings Inc.HUTCHMED (China) LtdAmphastar Pharmaceuticals, Inc.
Latest$606.88M
Ended 2025-12-31
$564.17M
Ended 2025-12-31
$548.51M
Ended 2025-12-31
$719.89M
Ended 2025-12-31
1 year earlier$713.14M
Ended 2024-12-31
$482.04M
Ended 2024-12-31
$630.20M
Ended 2024-12-31
$731.97M
Ended 2024-12-31
2 years earlier$863.50M
Ended 2023-12-31
$433.14M
Ended 2023-12-31
$838.00M
Ended 2023-12-31
$644.39M
Ended 2023-12-31
3 years earlier$1.00B
Ended 2022-12-31
$450.89M
Ended 2022-12-31
$426.41M
Ended 2022-12-31
$498.99M
Ended 2022-12-31
4 years earlier$1.77B
Ended 2021-12-31
$467.36M
Ended 2021-12-31
$356.13M
Ended 2021-12-31
$437.77M
Ended 2021-12-31